{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Community Acquired Pneumonia (CAP) treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Community Acquired Pneumonia (CAP).", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Community Acquired Pneumonia (CAP)\n\n**Definition:** Pneumonia acquired outside of hospitals or other healthcare facilities\n\n**Common Pathogens:**\n- Streptococcus pneumoniae\n- Haemophilus influenzae\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7 days\n- AZITHROMYCIN 500mg for 7 days\n- DOXYCYCLINE 100mg for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_000", "timestamp": "2025-10-29T21:36:43.470301", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Staphylococcus spp. infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Staphylococcus spp..", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Staphylococcus spp. based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Staphylococcus spp.** is commonly associated with:\n\n- Skin and Soft Tissue Infections\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- BACITRACIN\n- AMOXICILLIN\n- CEPHALEXIN\n- MUPIROCIN\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_001", "timestamp": "2025-10-29T21:36:43.470321", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Staphylococcus spp.", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about CSF shunt infections", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of CSF shunt infections.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# CSF shunt infections\n\n**Definition:** For confirmed shunt infections, the shunt should be removed and a temporary external ventricular drain inserted. The shunt should be sent for cultures.\n\n**First-Line Treatment (ICMR 2025):**\n- Vancomycin 25 mg/kg\n- Ceftazidime 2g\n- Cefepime 2g\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_002", "timestamp": "2025-10-29T21:36:43.470330", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "CSF shunt infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Rhinitis/Common cold?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Rhinitis/Common cold.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Rhinitis/Common cold.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Rhinitis/Common cold:\n\n**First-Line Treatment:**\n- paracetamol\n- Oseltamivir 75mg for 5-7 days\n\n**Alternative Options:**\n- decongestants\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_003", "timestamp": "2025-10-29T21:36:43.470335", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Rhinitis/Common cold", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating CSF Shunt Infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for CSF Shunt Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for CSF Shunt Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for CSF Shunt Infections:\n\n**First-Line Treatment:**\n- Vancomycin 25 mg/kg (IV) for q 8-12h\n- Ceftazidime 2g (IV)\n- Cefepime 2g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Ceftazidime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_004", "timestamp": "2025-10-29T21:36:43.470339", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "CSF Shunt Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Skin and Soft Tissue Infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Skin and Soft Tissue Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Skin and Soft Tissue Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Skin and Soft Tissue Infections:\n\n**First-Line Treatment:**\n- AMOXICILLIN-CLAVULANATE 625mg (PO) for 3 to 7 days\n- AMOXICILLIN-CLAVULANIC ACID 1.2g (IV) for 3 to 7 days\n\n**Alternative Options:**\n- CEFUROXIME\n- CLINDAMYCIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_005", "timestamp": "2025-10-29T21:36:43.470342", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Skin and Soft Tissue Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is Cefuroxime used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Cefuroxime and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Cefuroxime is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Cefuroxime** is used in the treatment of:\n\n- Diabetic foot infections (DFI)\n- Acute Osteomyelitis\n- Community Acquired Pneumonia\n- Bite wound infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_006", "timestamp": "2025-10-29T21:36:43.470345", "metadata": {"original_task_type": "drug_information", "drug": "Cefuroxime", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Febrile neutropenia syndrome?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Febrile neutropenia syndrome.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Febrile neutropenia syndrome\n\n**Definition:** Fever in a patient with neutropenia\n\n**First-Line Treatment (ICMR 2025):**\n- Piperacillin-tazobactam 4.5g\n- Cefoperazone-sulbactam 3g\n- Meropenem 1g\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_007", "timestamp": "2025-10-29T21:36:43.470349", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is CLINDAMYCIN used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about CLINDAMYCIN and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which CLINDAMYCIN is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**CLINDAMYCIN** is used in the treatment of:\n\n- Septic Abortion\n- Acute Prostatitis\n- Skin and Soft Tissue Infections\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Orbital Cellulitis and Retinitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_008", "timestamp": "2025-10-29T21:36:43.470352", "metadata": {"original_task_type": "drug_information", "drug": "CLINDAMYCIN", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Tertiary Peritonitis", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Tertiary Peritonitis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Tertiary Peritonitis\n\n**Definition:** A type of intra-abdominal infection, specifically healthcare-associated infection\n\n**First-Line Treatment (ICMR 2025):**\n- IMIPENEM-CILASTATIN 500 mg for 5-7 days\n- MEROPENEM 1g for 5-7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_009", "timestamp": "2025-10-29T21:36:43.470364", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Tertiary Peritonitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Febrile neutropenia syndrome", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Febrile neutropenia syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Febrile neutropenia syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_010", "timestamp": "2025-10-29T21:36:43.470373", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Antibiotic Associated Diarrhoea?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Antibiotic Associated Diarrhoea.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Antibiotic Associated Diarrhoea.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Antibiotic Associated Diarrhoea:\n\n**First-Line Treatment:**\n- VANCOMYCIN 125mg (PO) for Not specified\n- METRONIDAZOLE 500mg (IV) for Not specified\n\n**Common Pathogens:** Clostridium difficile\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_011", "timestamp": "2025-10-29T21:36:43.470378", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Antibiotic Associated Diarrhoea", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Burn wound infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Burn wound infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Burn wound infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Burn wound infections:\n\n**First-Line Treatment:**\n- Silver sulfadiazine 1% (Topical)\n- Silver nitrate 0.5% (Topical)\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_012", "timestamp": "2025-10-29T21:36:43.470381", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Burn wound infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Infections of Liver, Gall Bladder and Biliary tract treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Infections of Liver, Gall Bladder and Biliary tract.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Infections of Liver, Gall Bladder and Biliary tract\n\n**Definition:** Infections of Liver, Gall Bladder and Biliary tract\n\n**First-Line Treatment (ICMR 2025):**\n- Metronidazole 750mg for total 10 days\n- Ceftriaxone 2g\n- Metronidazole 750mg\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_013", "timestamp": "2025-10-29T21:36:43.470384", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Infections of Liver, Gall Bladder and Biliary tract", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Why is antibiotic resistance a problem?", "task_type": "education"}, "generator_reasoning_steps": ["Step 1: Concept Identification - Understanding the antimicrobial stewardship or resistance concept being queried.", "Step 2: Clinical Context - Relating the concept to real-world clinical practice and patient care.", "Step 3: Guideline Alignment - Connecting the concept to ICMR 2025 guidelines and recommendations.", "Step 4: Practical Implications - Explaining how this knowledge impacts antibiotic prescribing decisions.", "Step 5: Educational Response - Providing a clear, evidence-based explanation with practical examples."], "final_answer": "Antibiotic resistance is a major global health threat because:\n\n1. **Treatment failures**: Infections become harder or impossible to treat\n2. **Increased mortality**: Resistant infections lead to more deaths\n3. **Longer hospitalizations**: Patients require extended care\n4. **Higher healthcare costs**: More expensive drugs and procedures needed\n5. **Limited options**: Fewer effective antibiotics available\n6. **Spread of resistance**: Resistant genes can transfer between bacteria\n\nRational antibiotic use and adherence to guidelines like ICMR 2025 help combat resistance.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "EDUCATION_014", "timestamp": "2025-10-29T21:36:43.470388", "metadata": {"original_task_type": "education", "source": "AMR education"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Possible serious bacterial infection, PSBI (community acquired)?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Possible serious bacterial infection, PSBI (community acquired).", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Possible serious bacterial infection, PSBI (community acquired).", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Possible serious bacterial infection, PSBI (community acquired):\n\n**First-Line Treatment:**\n- Amoxicillin 20-40 mg/kg/dose (PO)\n- Ampicillin 50 mg/kg/dose (IV)\n- Ampicillin 75 mg/kg/dose (IV)\n\n**Alternative Options:**\n- Ampicillin\n- Cefotaxime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_015", "timestamp": "2025-10-29T21:36:43.470391", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Possible serious bacterial infection, PSBI (community acquired)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Invasive Candidiasis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Invasive Candidiasis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Invasive Candidiasis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_016", "timestamp": "2025-10-29T21:36:43.470397", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Tertiary Peritonitis?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Tertiary Peritonitis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Tertiary Peritonitis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Tertiary Peritonitis:\n\n**First-Line Treatment:**\n- IMIPENEM-CILASTATIN 500 mg (IV) for 5-7 days\n- MEROPENEM 1g (IV) for 5-7 days\n\n**Alternative Options:**\n- POLYMYXIN B\n- COLISTIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_017", "timestamp": "2025-10-29T21:36:43.470411", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Tertiary Peritonitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Enteric fever?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Enteric fever.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Enteric fever\n\n**Definition:** Blood culture remains the gold standard.\n\n**First-Line Treatment (ICMR 2025):**\n- Azithromycin 20 mg /kg/day for 7 days\n- Cotrimoxazole 960 mg for 2 weeks\n- Ceftriaxone 2g for 10-14 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_018", "timestamp": "2025-10-29T21:36:43.470421", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Enteric fever", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Conjunctivitis treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Conjunctivitis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Conjunctivitis\n\n**Definition:** Infection of the conjunctiva, can be bacterial or viral\n\n**Common Pathogens:**\n- HSV\n- Adenovirus\n- CMV\n\n**First-Line Treatment (ICMR 2025):**\n- TOBRAMYCIN Not specified for 7 days\n- GENTAMICIN Not specified for 7 days\n- ACYCLOVIR 20 mg/kg/dose for 14 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_019", "timestamp": "2025-10-29T21:36:43.470425", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Conjunctivitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Bronchitis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Bronchitis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Bronchitis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Bronchitis:\n\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_020", "timestamp": "2025-10-29T21:36:43.470430", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Bronchitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Invasive Candidiasis?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Invasive Candidiasis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Invasive Candidiasis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_021", "timestamp": "2025-10-29T21:36:43.470438", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Rhinitis/Common cold", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Rhinitis/Common cold.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Rhinitis/Common cold\n\n**Definition:** Viral rhinitis\n\n**First-Line Treatment (ICMR 2025):**\n- paracetamol\n- Oseltamivir 75mg for 5-7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_022", "timestamp": "2025-10-29T21:36:43.470443", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Rhinitis/Common cold", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Botulism", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Botulism.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Botulism\n\n**Definition:** Botulism is a serious medical emergency that requires immediate treatment. Botulinum antitoxins to be administered as soon as possible, this can neutralize botulinum toxin and prevent further damage.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_023", "timestamp": "2025-10-29T21:36:43.470446", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Botulism", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "When should I prescribe Teicoplanin?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Teicoplanin and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Teicoplanin is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Teicoplanin** is used in the treatment of:\n\n- Central Line-Associated Bloodstream Infection (CLABSI)\n- Infective Endocarditis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_024", "timestamp": "2025-10-29T21:36:43.470449", "metadata": {"original_task_type": "drug_information", "drug": "Teicoplanin", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Urinary Tract Infections", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Urinary Tract Infections.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Urinary Tract Infections\n\n**Definition:** Infections involving the urinary system, including cystitis and pyelonephritis, characterized by symptoms such as dysuria, frequency, urgency, and fever\n\n**First-Line Treatment (ICMR 2025):**\n- NITROFURANTOIN 100 mg for 5 days\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7-10 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_025", "timestamp": "2025-10-29T21:36:43.470453", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Urinary Tract Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is ANIDULAFUNGIN used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about ANIDULAFUNGIN and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which ANIDULAFUNGIN is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**ANIDULAFUNGIN** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_026", "timestamp": "2025-10-29T21:36:43.470457", "metadata": {"original_task_type": "drug_information", "drug": "ANIDULAFUNGIN", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Febrile neutropenia syndrome?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Febrile neutropenia syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Febrile neutropenia syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_027", "timestamp": "2025-10-29T21:36:43.470465", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Acute Gastroenteritis?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Acute Gastroenteritis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Acute Gastroenteritis\n\n**Definition:** Mostly caused by viruses or self-limiting bacterial pathogens.\n\n**First-Line Treatment (ICMR 2025):**\n- Azithromycin 500mg for 3 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_028", "timestamp": "2025-10-29T21:36:43.470471", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Acute Gastroenteritis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "When should I prescribe Amoxicillin-Clavulanic acid?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Amoxicillin-Clavulanic acid and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Amoxicillin-Clavulanic acid is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Amoxicillin-Clavulanic acid** is used in the treatment of:\n\n- Bite wound infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_029", "timestamp": "2025-10-29T21:36:43.470474", "metadata": {"original_task_type": "drug_information", "drug": "Amoxicillin-Clavulanic acid", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Pseudomonas aeruginosa infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Pseudomonas aeruginosa.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Pseudomonas aeruginosa based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Pseudomonas aeruginosa** is commonly associated with:\n\n- Acute Osteomyelitis\n\n**Effective antibiotics include:**\n- Cloxacillin\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_030", "timestamp": "2025-10-29T21:36:43.470477", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Pseudomonas aeruginosa", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Neonatal Infections treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Neonatal Infections.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Neonatal Infections\n\n**Definition:** Infections in neonates, including those with specific gestational age and postnatal age considerations\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 15 mg/kg/dose for 5-7 days or 7-14 days\n- CIPROFLOXACIN 10 mg/kg/dose for 5-7 days or 7-14 days\n- CEFOTAXIME Not specified for 21 days\n\n**Special Populations:** Consider dose adjustments or alternative agents\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_031", "timestamp": "2025-10-29T21:36:43.470483", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Neonatal Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Encephalitis syndrome?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Encephalitis syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Encephalitis syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Encephalitis syndrome:\n\n**First-Line Treatment:**\n- Acyclovir 10 mg/kg (IV) for 14-21 days\n- Ceftriaxone 2g (IV)\n- Doxycycline 100mg (PO/IV) for 10-14 days\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_032", "timestamp": "2025-10-29T21:36:43.470487", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Encephalitis syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Skin and Soft Tissue Infections", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Skin and Soft Tissue Infections.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Skin and Soft Tissue Infections\n\n**Definition:** Infections involving clean incised wounds, contused lacerated wounds, and contaminated wounds\n\n**First-Line Treatment (ICMR 2025):**\n- AMOXICILLIN-CLAVULANATE 625mg for 3 to 7 days\n- AMOXICILLIN-CLAVULANIC ACID 1.2g for 3 to 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_033", "timestamp": "2025-10-29T21:36:43.470492", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Skin and Soft Tissue Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is Penicillin G used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Penicillin G and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Penicillin G is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Penicillin G** is used in the treatment of:\n\n- Infective Endocarditis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_034", "timestamp": "2025-10-29T21:36:43.470497", "metadata": {"original_task_type": "drug_information", "drug": "Penicillin G", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about COLISTIN", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about COLISTIN and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which COLISTIN is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**COLISTIN** is used in the treatment of:\n\n- Healthcare Associated Infections\n- Tertiary Peritonitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_035", "timestamp": "2025-10-29T21:36:43.470500", "metadata": {"original_task_type": "drug_information", "drug": "COLISTIN", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Bronchitis treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Bronchitis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Bronchitis\n\n**Definition:** Bronchitis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_036", "timestamp": "2025-10-29T21:36:43.470509", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Bronchitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Mycobacterium tuberculosis?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Mycobacterium tuberculosis.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Mycobacterium tuberculosis based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Mycobacterium tuberculosis** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_037", "timestamp": "2025-10-29T21:36:43.470512", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Mycobacterium tuberculosis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Acute Undifferentiated Febrile illness?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Acute Undifferentiated Febrile illness.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Acute Undifferentiated Febrile illness.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Acute Undifferentiated Febrile illness:\n\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_038", "timestamp": "2025-10-29T21:36:43.470515", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Gram Negative bacilli?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Gram Negative bacilli.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Gram Negative bacilli based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Gram Negative bacilli** is commonly associated with:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- CEFTRIAXONE\n- AMOXICILLIN\n- CLINDAMYCIN\n- COTRIMOXAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_039", "timestamp": "2025-10-29T21:36:43.470518", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Gram Negative bacilli", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is Ceftazidime-avibactam used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Ceftazidime-avibactam and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Ceftazidime-avibactam is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Ceftazidime-avibactam** is used in the treatment of:\n\n- Febrile neutropenia syndrome\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_040", "timestamp": "2025-10-29T21:36:43.470521", "metadata": {"original_task_type": "drug_information", "drug": "Ceftazidime-avibactam", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Infective Endocarditis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Infective Endocarditis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Infective Endocarditis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Infective Endocarditis:\n\n**First-Line Treatment:**\n- Penicillin G 4 million units (IV) for 4 weeks\n- Ampicillin 2g (IV) for 4 weeks\n- Gentamicin 1mg/kg (IM or IV) for first 2 weeks\n\n**Alternative Options:**\n- Vancomycin\n- Gentamicin\n\n**Common Pathogens:** Staphylococcus aureus, Coagulase-negative Staphylococci, Enterococci\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_041", "timestamp": "2025-10-29T21:36:43.470525", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Infective Endocarditis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Antimicrobial Treatment Guidelines", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Antimicrobial Treatment Guidelines.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Antimicrobial Treatment Guidelines.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Antimicrobial Treatment Guidelines:\n\n**First-Line Treatment:**\n- MEROPENEM 1g (IV) for Not specified\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_042", "timestamp": "2025-10-29T21:36:43.470528", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Antimicrobial Treatment Guidelines", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What drugs are effective for Vibrio spp.?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Vibrio spp..", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Vibrio spp. based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Vibrio spp.** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_043", "timestamp": "2025-10-29T21:36:43.470530", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Vibrio spp.", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Febrile neutropenia syndrome", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Febrile neutropenia syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Febrile neutropenia syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_044", "timestamp": "2025-10-29T21:36:43.470533", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Streptococcus pneumoniae treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Streptococcus pneumoniae.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Streptococcus pneumoniae based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Streptococcus pneumoniae** is commonly associated with:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Community Acquired Pneumonia (CAP)\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- AZITHROMYCIN\n- CEFTRIAXONE\n- PIPERACILLIN-TAZOBACTAM\n- AMOXICILLIN\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_045", "timestamp": "2025-10-29T21:36:43.470536", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Streptococcus pneumoniae", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Community Acquired Pneumonia (CAP)?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Community Acquired Pneumonia (CAP).", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Community Acquired Pneumonia (CAP)\n\n**Definition:** Pneumonia acquired outside of hospitals or other healthcare facilities\n\n**Common Pathogens:**\n- Streptococcus pneumoniae\n- Haemophilus influenzae\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7 days\n- AZITHROMYCIN 500mg for 7 days\n- DOXYCYCLINE 100mg for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_046", "timestamp": "2025-10-29T21:36:43.470539", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is Tinidazole used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Tinidazole and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Tinidazole is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Tinidazole** is used in the treatment of:\n\n- Infections of Liver, Gall Bladder and Biliary tract\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_047", "timestamp": "2025-10-29T21:36:43.470542", "metadata": {"original_task_type": "drug_information", "drug": "Tinidazole", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is Polymyxin B used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Polymyxin B and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Polymyxin B is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Polymyxin B** is used in the treatment of:\n\n- Febrile neutropenia syndrome\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_048", "timestamp": "2025-10-29T21:36:43.470544", "metadata": {"original_task_type": "drug_information", "drug": "Polymyxin B", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Bite wound infections treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Bite wound infections.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Bite wound infections\n\n**Definition:** Wound infections caused by animal (dog/cat/monkey/human) bites.\n\n**Common Pathogens:**\n- Staphylococcus aureus\n- Pasteurella multocida\n- Anaerobes\n- Capnocytophaga canimorsus\n- Viridans streptococci\n\n**First-Line Treatment (ICMR 2025):**\n- Amoxicillin-clavulanic acid 625mg for 3 to 5 days\n- Piperacillin-tazobactam 4.5g for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_049", "timestamp": "2025-10-29T21:36:43.470548", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Bite wound infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Infective Endocarditis treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Infective Endocarditis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Infective Endocarditis\n\n**Definition:** Infection of the heart valves, typically requiring empirical antibiotic therapy pending blood culture results\n\n**First-Line Treatment (ICMR 2025):**\n- PENICILLIN G 4 million units for 4 weeks\n- AMPICILLIN 2g for 4 weeks\n- VANCOMYCIN 15mg/kg for 4-6 weeks\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_050", "timestamp": "2025-10-29T21:36:43.470551", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Infective Endocarditis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Staphylococcus aureus treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Staphylococcus aureus.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Staphylococcus aureus based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Staphylococcus aureus** is commonly associated with:\n\n- Acute Osteomyelitis\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Bite wound infections\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- Amoxicillin-Clavulanic acid\n- CEFTRIAXONE\n- AMOXICILLIN\n- Amoxicillin-clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_051", "timestamp": "2025-10-29T21:36:43.470554", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Staphylococcus aureus", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is CEFUROXIME used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about CEFUROXIME and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which CEFUROXIME is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**CEFUROXIME** is used in the treatment of:\n\n- Skin and Soft Tissue Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_052", "timestamp": "2025-10-29T21:36:43.470556", "metadata": {"original_task_type": "drug_information", "drug": "CEFUROXIME", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Viridans streptococci infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Viridans streptococci.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Viridans streptococci based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Viridans streptococci** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_053", "timestamp": "2025-10-29T21:36:43.470559", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Viridans streptococci", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about TRIFLURIDINE", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about TRIFLURIDINE and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which TRIFLURIDINE is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**TRIFLURIDINE** is used in the treatment of:\n\n- Conjunctivitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_054", "timestamp": "2025-10-29T21:36:43.470561", "metadata": {"original_task_type": "drug_information", "drug": "TRIFLURIDINE", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Escherichia coli infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Escherichia coli.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Escherichia coli based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Escherichia coli** is commonly associated with:\n\n- Acute Osteomyelitis\n\n**Effective antibiotics include:**\n- Cloxacillin\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_055", "timestamp": "2025-10-29T21:36:43.470564", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Escherichia coli", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Febrile neutropenia syndrome?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Febrile neutropenia syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Febrile neutropenia syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_056", "timestamp": "2025-10-29T21:36:43.470567", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Orthopaedic implant associated infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Orthopaedic implant associated infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Orthopaedic implant associated infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Orthopaedic implant associated infections:\n\n**First-Line Treatment:**\n- Debridement\n- Targeted antibiotic\n\n**Alternative Options:**\n- As in acute osteomyelitis\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_057", "timestamp": "2025-10-29T21:36:43.470570", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Orthopaedic implant associated infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Community Acquired Pneumonia (CAP)?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Community Acquired Pneumonia (CAP).", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Community Acquired Pneumonia (CAP).", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Community Acquired Pneumonia (CAP):\n\n**First-Line Treatment:**\n- PIPERACILLIN-TAZOBACTAM 4.5g (IV) for 7 days\n- AZITHROMYCIN 500mg (PO) for 7 days\n- DOXYCYCLINE 100mg (PO) for 7 days\n\n**Alternative Options:**\n- IMIPENEM\n- MEROPENEM\n\n**Common Pathogens:** Streptococcus pneumoniae, Haemophilus influenzae\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_058", "timestamp": "2025-10-29T21:36:43.470574", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Septic Abortion?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Septic Abortion.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Septic Abortion.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Septic Abortion:\n\n**First-Line Treatment:**\n- AMPICILLIN 2g (IV) for 7-10 days\n- GENTAMICIN 5 mg/kg (IV) for 7-10 days\n- METRONIDAZOLE 500 mg (IV) for 7-10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_059", "timestamp": "2025-10-29T21:36:43.470577", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Septic Abortion", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What are the indications for Oseltamivir?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Oseltamivir and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Oseltamivir is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Oseltamivir** is used in the treatment of:\n\n- Rhinitis/Common cold\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_060", "timestamp": "2025-10-29T21:36:43.470579", "metadata": {"original_task_type": "drug_information", "drug": "Oseltamivir", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Eikenella corrodens treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Eikenella corrodens.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Eikenella corrodens based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Eikenella corrodens** is commonly associated with:\n\n- Bite wound infections\n- Infective Endocarditis\n\n**Effective antibiotics include:**\n- Meropenem\n- Gentamicin\n- Amoxicillin-Clavulanic acid\n- Vancomycin\n- Ampicillin\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_061", "timestamp": "2025-10-29T21:36:43.470582", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Eikenella corrodens", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Bite wound infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Bite wound infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Bite wound infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Bite wound infections:\n\n**First-Line Treatment:**\n- Amoxicillin-clavulanic acid 625mg (PO) for 3 to 5 days\n- Piperacillin-tazobactam 4.5g (IV) for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n**Alternative Options:**\n- Cefuroxime\n- Doxycycline\n\n**Common Pathogens:** Staphylococcus aureus, Pasteurella multocida, Anaerobes\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_062", "timestamp": "2025-10-29T21:36:43.470588", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Bite wound infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Acute Prostatitis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Acute Prostatitis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Acute Prostatitis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Acute Prostatitis:\n\n**First-Line Treatment:**\n- CEFTRIAXONE 500mg (IM) for 10 days\n- DOXYCYCLINE 100mg (PO) for 10 days\n- CEFIXIME 800mg (PO) for 10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_063", "timestamp": "2025-10-29T21:36:43.470591", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Acute Prostatitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Haemophilus influenzae infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Haemophilus influenzae.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Haemophilus influenzae based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Haemophilus influenzae** is commonly associated with:\n\n- Bite wound infections\n- Community Acquired Pneumonia (CAP)\n\n**Effective antibiotics include:**\n- Amoxicillin-Clavulanic acid\n- AZITHROMYCIN\n- PIPERACILLIN-TAZOBACTAM\n- Amoxicillin-clavulanic acid\n- Valacyclovir/Acyclovir\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_064", "timestamp": "2025-10-29T21:36:43.470594", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Haemophilus influenzae", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Ceftazidime-avibactam", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Ceftazidime-avibactam and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Ceftazidime-avibactam is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Ceftazidime-avibactam** is used in the treatment of:\n\n- Febrile neutropenia syndrome\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_065", "timestamp": "2025-10-29T21:36:43.470827", "metadata": {"original_task_type": "drug_information", "drug": "Ceftazidime-avibactam", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Neonatal Infections", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Neonatal Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Neonatal Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Neonatal Infections:\n\n**First-Line Treatment:**\n- PIPERACILLIN-TAZOBACTAM 15 mg/kg/dose (IV) for 5-7 days or 7-14 days\n- CIPROFLOXACIN 10 mg/kg/dose (IV) for 5-7 days or 7-14 days\n- CEFOTAXIME Not specified (Not specified) for 21 days\n\n**Alternative Options:**\n- TEICOPLANIN\n- AMPICILLIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_066", "timestamp": "2025-10-29T21:36:43.470839", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Neonatal Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for CSF shunt infections", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for CSF shunt infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for CSF shunt infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for CSF shunt infections:\n\n**First-Line Treatment:**\n- Vancomycin 25 mg/kg (IV)\n- Ceftazidime 2g (IV)\n- Cefepime 2g (IV)\n\n**Alternative Options:**\n- Vancomycin\n- Meropenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_067", "timestamp": "2025-10-29T21:36:43.470843", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "CSF shunt infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the difference between first-line and alternative drugs?", "task_type": "education"}, "generator_reasoning_steps": ["Step 1: Concept Identification - Understanding the antimicrobial stewardship or resistance concept being queried.", "Step 2: Clinical Context - Relating the concept to real-world clinical practice and patient care.", "Step 3: Guideline Alignment - Connecting the concept to ICMR 2025 guidelines and recommendations.", "Step 4: Practical Implications - Explaining how this knowledge impacts antibiotic prescribing decisions.", "Step 5: Educational Response - Providing a clear, evidence-based explanation with practical examples."], "final_answer": "**First-line drugs** are the preferred initial treatment options based on:\n- Proven efficacy\n- Safety profile\n- Cost-effectiveness\n- Local resistance patterns\n\n**Alternative drugs** are used when:\n- Patient has allergies to first-line agents\n- First-line therapy has failed\n- Culture results indicate resistance\n- Specific contraindications exist\n\nICMR guidelines provide both first-line and alternative options to guide rational antibiotic use.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "EDUCATION_068", "timestamp": "2025-10-29T21:36:43.470846", "metadata": {"original_task_type": "education", "source": "AMR education"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Healthcare Associated Infections?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Healthcare Associated Infections.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Healthcare Associated Infections\n\n**Definition:** Fever in ICU can be due to infective or non-infective causes. Empiric therapy for HAI would depend upon the infectious syndrome, organism prevalent in the unit, local resistance pattern.\n\n**Common Pathogens:**\n- C. glabrata\n- C. auris\n- C. krusei\n- E. coli\n- Pseudomonas spp.\n\n**First-Line Treatment (ICMR 2025):**\n- MICAFUNGIN 100 mg for Not specified\n- ANIDULAFUNGIN 200 mg loading dose, then 100 mg daily for Not specified\n- CASPOFUNGIN 70 mg loading dose, then 50 mg daily for Not specified\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_069", "timestamp": "2025-10-29T21:36:43.470850", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Healthcare Associated Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is PIPERACILLIN-TAZOBACTAM used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about PIPERACILLIN-TAZOBACTAM and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which PIPERACILLIN-TAZOBACTAM is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**PIPERACILLIN-TAZOBACTAM** is used in the treatment of:\n\n- Urinary Tract Infections\n- Septic Abortion\n- Acute Prostatitis\n- Community Acquired Pneumonia (CAP)\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_070", "timestamp": "2025-10-29T21:36:43.470853", "metadata": {"original_task_type": "drug_information", "drug": "PIPERACILLIN-TAZOBACTAM", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Enteric fever", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Enteric fever.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Enteric fever\n\n**Definition:** Blood culture remains the gold standard.\n\n**First-Line Treatment (ICMR 2025):**\n- Azithromycin 20 mg /kg/day for 7 days\n- Cotrimoxazole 960 mg for 2 weeks\n- Ceftriaxone 2g for 10-14 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_071", "timestamp": "2025-10-29T21:36:43.470857", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Enteric fever", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Diabetic foot infections (DFI)?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Diabetic foot infections (DFI).", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Diabetic foot infections (DFI)\n\n**Definition:** Local infection with 0.5cm to < 2cm erythema\n\n**First-Line Treatment (ICMR 2025):**\n- Cloxacillin 500 mg for 1 to 2 weeks\n- Cephalexin 500 mg for 1 to 2 weeks\n- Cefadroxil 500 mg for 1 to 2 weeks\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_072", "timestamp": "2025-10-29T21:36:43.470860", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Diabetic foot infections (DFI)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is antimicrobial stewardship?", "task_type": "education"}, "generator_reasoning_steps": ["Step 1: Concept Identification - Understanding the antimicrobial stewardship or resistance concept being queried.", "Step 2: Clinical Context - Relating the concept to real-world clinical practice and patient care.", "Step 3: Guideline Alignment - Connecting the concept to ICMR 2025 guidelines and recommendations.", "Step 4: Practical Implications - Explaining how this knowledge impacts antibiotic prescribing decisions.", "Step 5: Educational Response - Providing a clear, evidence-based explanation with practical examples."], "final_answer": "Antimicrobial stewardship refers to coordinated interventions designed to improve and measure the appropriate use of antimicrobials by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. Key principles include:\n\n- Using the right antibiotic for the right infection\n- Using narrow-spectrum agents when possible\n- Prescribing for appropriate durations\n- De-escalating therapy based on culture results\n- Avoiding antibiotics for viral infections\n\nThis helps prevent antimicrobial resistance and improves patient outcomes.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "EDUCATION_073", "timestamp": "2025-10-29T21:36:43.470864", "metadata": {"original_task_type": "education", "source": "AMR education"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Invasive Candidiasis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Invasive Candidiasis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Invasive Candidiasis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_074", "timestamp": "2025-10-29T21:36:43.470868", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Acute Undifferentiated Febrile illness treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Acute Undifferentiated Febrile illness.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Acute Undifferentiated Febrile illness\n\n**Definition:** Acute febrile syndrome presents with headache, chills, or muscle and joint pains and is usually viral and often resolves without treatment. Acute febrile syndrome can also be caused by bacterial, rickettsial or parasitic infections and non-infective conditions like autoimmune disorders.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_075", "timestamp": "2025-10-29T21:36:43.470872", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Infective Endocarditis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Infective Endocarditis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Infective Endocarditis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Infective Endocarditis:\n\n**First-Line Treatment:**\n- Penicillin G 4 million units (IV) for 4 weeks\n- Ampicillin 2g (IV) for 4 weeks\n- Gentamicin 1mg/kg (IM or IV) for first 2 weeks\n\n**Alternative Options:**\n- Vancomycin\n- Gentamicin\n\n**Common Pathogens:** Staphylococcus aureus, Coagulase-negative Staphylococci, Enterococci\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_076", "timestamp": "2025-10-29T21:36:43.470875", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Infective Endocarditis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Amoxicillin-clavulanic Acid", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Amoxicillin-clavulanic Acid and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Amoxicillin-clavulanic Acid is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Amoxicillin-clavulanic Acid** is used in the treatment of:\n\n- Infections of Liver, Gall Bladder and Biliary tract\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_077", "timestamp": "2025-10-29T21:36:43.470878", "metadata": {"original_task_type": "drug_information", "drug": "Amoxicillin-clavulanic Acid", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Bite wound infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Bite wound infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Bite wound infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Bite wound infections:\n\n**First-Line Treatment:**\n- Amoxicillin-clavulanic acid 625mg (PO) for 3 to 5 days\n- Piperacillin-tazobactam 4.5g (IV) for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n**Alternative Options:**\n- Cefuroxime\n- Doxycycline\n\n**Common Pathogens:** Staphylococcus aureus, Pasteurella multocida, Anaerobes\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_078", "timestamp": "2025-10-29T21:36:43.470882", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Bite wound infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is IMIPENEM-CILASTATIN used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about IMIPENEM-CILASTATIN and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which IMIPENEM-CILASTATIN is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**IMIPENEM-CILASTATIN** is used in the treatment of:\n\n- Tertiary Peritonitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_079", "timestamp": "2025-10-29T21:36:43.470885", "metadata": {"original_task_type": "drug_information", "drug": "IMIPENEM-CILASTATIN", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Possible serious bacterial infection, PSBI (community acquired)?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Possible serious bacterial infection, PSBI (community acquired).", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Possible serious bacterial infection, PSBI (community acquired).", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Possible serious bacterial infection, PSBI (community acquired):\n\n**First-Line Treatment:**\n- Amoxicillin 20-40 mg/kg/dose (PO)\n- Ampicillin 50 mg/kg/dose (IV)\n- Ampicillin 75 mg/kg/dose (IV)\n\n**Alternative Options:**\n- Ampicillin\n- Cefotaxime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_080", "timestamp": "2025-10-29T21:36:43.470888", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Possible serious bacterial infection, PSBI (community acquired)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Cladophialophora treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Cladophialophora.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Cladophialophora based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Cladophialophora** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_081", "timestamp": "2025-10-29T21:36:43.470891", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Cladophialophora", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is empirical antibiotic therapy?", "task_type": "education"}, "generator_reasoning_steps": ["Step 1: Concept Identification - Understanding the antimicrobial stewardship or resistance concept being queried.", "Step 2: Clinical Context - Relating the concept to real-world clinical practice and patient care.", "Step 3: Guideline Alignment - Connecting the concept to ICMR 2025 guidelines and recommendations.", "Step 4: Practical Implications - Explaining how this knowledge impacts antibiotic prescribing decisions.", "Step 5: Educational Response - Providing a clear, evidence-based explanation with practical examples."], "final_answer": "Empirical antibiotic therapy is the initial treatment given before laboratory culture and sensitivity results are available. It is based on:\n\n1. **Clinical diagnosis** of the infection\n2. **Most likely pathogens** for that infection\n3. **Local resistance patterns**\n4. **Patient factors** (age, comorbidities, allergies)\n5. **Guideline recommendations** (like ICMR 2025)\n\n**Key principle**: Start broad-spectrum therapy, then de-escalate to narrow-spectrum based on culture results (de-escalation strategy).\n\nThis approach ensures timely treatment while minimizing unnecessary broad-spectrum use.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "EDUCATION_082", "timestamp": "2025-10-29T21:36:43.470894", "metadata": {"original_task_type": "education", "source": "AMR education"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "When should I prescribe CASPOFUNGIN?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about CASPOFUNGIN and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which CASPOFUNGIN is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**CASPOFUNGIN** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_083", "timestamp": "2025-10-29T21:36:43.470897", "metadata": {"original_task_type": "drug_information", "drug": "CASPOFUNGIN", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Skin and Soft Tissue Infections", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Skin and Soft Tissue Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Skin and Soft Tissue Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Skin and Soft Tissue Infections:\n\n**First-Line Treatment:**\n- AMOXICILLIN-CLAVULANATE 625mg (PO) for 3 to 7 days\n- AMOXICILLIN-CLAVULANIC ACID 1.2g (IV) for 3 to 7 days\n\n**Alternative Options:**\n- CEFUROXIME\n- CLINDAMYCIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_084", "timestamp": "2025-10-29T21:36:43.470900", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Skin and Soft Tissue Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Nocardia?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Nocardia.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Nocardia based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Nocardia** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_085", "timestamp": "2025-10-29T21:36:43.470903", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Nocardia", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Acute Undifferentiated Febrile illness", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Acute Undifferentiated Febrile illness.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Acute Undifferentiated Febrile illness\n\n**Definition:** Acute febrile syndrome presents with headache, chills, or muscle and joint pains and is usually viral and often resolves without treatment. Acute febrile syndrome can also be caused by bacterial, rickettsial or parasitic infections and non-infective conditions like autoimmune disorders.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_086", "timestamp": "2025-10-29T21:36:43.470907", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What are the indications for Cephalexin?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Cephalexin and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Cephalexin is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Cephalexin** is used in the treatment of:\n\n- Diabetic foot infections (DFI)\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_087", "timestamp": "2025-10-29T21:36:43.470910", "metadata": {"original_task_type": "drug_information", "drug": "Cephalexin", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Community Acquired Pneumonia (CAP)", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Community Acquired Pneumonia (CAP).", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Community Acquired Pneumonia (CAP)\n\n**Definition:** Pneumonia acquired outside of hospitals or other healthcare facilities\n\n**Common Pathogens:**\n- Streptococcus pneumoniae\n- Haemophilus influenzae\n\n**First-Line Treatment (ICMR 2025):**\n- PIPERACILLIN-TAZOBACTAM 4.5g for 7 days\n- AZITHROMYCIN 500mg for 7 days\n- DOXYCYCLINE 100mg for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_088", "timestamp": "2025-10-29T21:36:43.470913", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Community Acquired Pneumonia (CAP)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Aeromonas hydrophila?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Aeromonas hydrophila.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Aeromonas hydrophila based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Aeromonas hydrophila** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_089", "timestamp": "2025-10-29T21:36:43.470916", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Aeromonas hydrophila", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is Cefotaxime used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Cefotaxime and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Cefotaxime is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Cefotaxime** is used in the treatment of:\n\n- Meningitis syndrome\n- Community Acquired Pneumonia\n- Infections in Asplenia\n- Possible serious bacterial infection, PSBI (community acquired)\n- Neonatal Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_090", "timestamp": "2025-10-29T21:36:43.470919", "metadata": {"original_task_type": "drug_information", "drug": "Cefotaxime", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Capnocytophaga canimorsus treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Capnocytophaga canimorsus.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Capnocytophaga canimorsus based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Capnocytophaga canimorsus** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_091", "timestamp": "2025-10-29T21:36:43.470922", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Capnocytophaga canimorsus", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "When should I prescribe FOSCARNET?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about FOSCARNET and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which FOSCARNET is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**FOSCARNET** is used in the treatment of:\n\n- Orbital Cellulitis and Retinitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_092", "timestamp": "2025-10-29T21:36:43.470925", "metadata": {"original_task_type": "drug_information", "drug": "FOSCARNET", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Listeria monocytogenes?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Listeria monocytogenes.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Listeria monocytogenes based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Listeria monocytogenes** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_093", "timestamp": "2025-10-29T21:36:43.470929", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Listeria monocytogenes", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is CLOTRIMAZOLE used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about CLOTRIMAZOLE and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which CLOTRIMAZOLE is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**CLOTRIMAZOLE** is used in the treatment of:\n\n- Oropharyngeal Candidiasis\n- Superficial Abscesses and Other Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_094", "timestamp": "2025-10-29T21:36:43.470932", "metadata": {"original_task_type": "drug_information", "drug": "CLOTRIMAZOLE", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Bronchitis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Bronchitis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Bronchitis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Bronchitis:\n\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_095", "timestamp": "2025-10-29T21:36:43.470936", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Bronchitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Febrile neutropenia syndrome", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Febrile neutropenia syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Febrile neutropenia syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_096", "timestamp": "2025-10-29T21:36:43.470939", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Community Acquired Pneumonia?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Community Acquired Pneumonia.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Community Acquired Pneumonia.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Community Acquired Pneumonia:\n\n**First-Line Treatment:**\n- Amoxicillin 1g (PO) for 5-7 days\n- Amoxicillin-clavulanate 1g (PO) for 5-7 days\n- Ceftriaxone 2g (IV) for 5-7 days\n\n**Alternative Options:**\n- Azithromycin\n- Clarithromycin\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_097", "timestamp": "2025-10-29T21:36:43.470942", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Community Acquired Pneumonia", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Periocular infections (Eyelid infections, Orbital cellulitis)", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Periocular infections (Eyelid infections, Orbital cellulitis).", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Periocular infections (Eyelid infections, Orbital cellulitis).", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Periocular infections (Eyelid infections, Orbital cellulitis):\n\n**First-Line Treatment:**\n- AMOXICILLIN 90/6.4 mg/kg/day (PO) for 5-7 days\n- COTRIMOXAZOLE 5 mg/kg per day (PO) for 5 to 7 days\n- CLINDAMYCIN 10mg/kg/dose (max 600 mg/dose) (PO) for 5 to 7 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- TRIMETHOPRIM-SULFAMETHOXAZOLE\n\n**Common Pathogens:** Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_098", "timestamp": "2025-10-29T21:36:43.470947", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Periocular infections (Eyelid infections, Orbital cellulitis)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Invasive Candidiasis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Invasive Candidiasis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Invasive Candidiasis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Invasive Candidiasis:\n\n**First-Line Treatment:**\n- Micafungin 100 mg (IV)\n- Anidulafungin 200 mg (IV)\n- Caspofungin 70 mg (IV)\n\n**Alternative Options:**\n- Liposomal Amphotericin B\n\n**Common Pathogens:** Candida albicans, C. glabrata, C. parapsilosis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_099", "timestamp": "2025-10-29T21:36:43.470951", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Invasive Candidiasis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Possible serious bacterial infection, PSBI (community acquired) treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Possible serious bacterial infection, PSBI (community acquired).", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Possible serious bacterial infection, PSBI (community acquired)\n\n**Definition:** Consider PSBI if any one of the following signs is present:\n\tNot able to feed since birth or stopped feeding well (confirmed by observation)\n\tNo movement or movement only on stimulation\n\tConvulsions\n\tFast breathing (60 breaths per minute or more) in infants younger than 7 days of age\n\tSevere chest in-drawing\n\tFever ( 38.0 C)\n\tLow body temperature (< 35.5 C)\nSigns are nonspecific.\n\n**First-Line Treatment (ICMR 2025):**\n- Amoxicillin 20-40 mg/kg/dose\n- Ampicillin 50 mg/kg/dose\n- Ampicillin 75 mg/kg/dose\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_100", "timestamp": "2025-10-29T21:36:43.470957", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Possible serious bacterial infection, PSBI (community acquired)", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is LIPosomal AMphotericin B used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about LIPosomal AMphotericin B and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which LIPosomal AMphotericin B is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**LIPosomal AMphotericin B** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_101", "timestamp": "2025-10-29T21:36:43.470960", "metadata": {"original_task_type": "drug_information", "drug": "LIPosomal AMphotericin B", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Infections in Asplenia", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Infections in Asplenia.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Infections in Asplenia\n\n**Definition:** null\n\n**First-Line Treatment (ICMR 2025):**\n- Ceftriaxone 2g for 7 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_102", "timestamp": "2025-10-29T21:36:43.470963", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Infections in Asplenia", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Rhinitis/Common cold", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Rhinitis/Common cold.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Rhinitis/Common cold.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Rhinitis/Common cold:\n\n**First-Line Treatment:**\n- paracetamol\n- Oseltamivir 75mg for 5-7 days\n\n**Alternative Options:**\n- decongestants\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_103", "timestamp": "2025-10-29T21:36:43.470966", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Rhinitis/Common cold", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Explain Bronchitis treatment", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Bronchitis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Bronchitis\n\n**Definition:** Bronchitis\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_104", "timestamp": "2025-10-29T21:36:43.470969", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Bronchitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Acute Osteomyelitis?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Acute Osteomyelitis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Acute Osteomyelitis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Acute Osteomyelitis:\n\n**First-Line Treatment:**\n- Cloxacillin 2g (IV)\n\n**Alternative Options:**\n- Amoxicillin-clavulanic acid\n- Cefazolin\n\n**Common Pathogens:** Staphylococcus aureus, Streptococci, Escherichia coli\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_105", "timestamp": "2025-10-29T21:36:43.470973", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Acute Osteomyelitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What are the indications for CIPROFLOXACIN?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about CIPROFLOXACIN and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which CIPROFLOXACIN is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**CIPROFLOXACIN** is used in the treatment of:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n- Neonatal Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_106", "timestamp": "2025-10-29T21:36:43.470976", "metadata": {"original_task_type": "drug_information", "drug": "CIPROFLOXACIN", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Antibiotic Associated Diarrhoea", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Antibiotic Associated Diarrhoea.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Antibiotic Associated Diarrhoea.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Antibiotic Associated Diarrhoea:\n\n**First-Line Treatment:**\n- VANCOMYCIN 125mg (PO) for Not specified\n- METRONIDAZOLE 500mg (IV) for Not specified\n\n**Common Pathogens:** Clostridium difficile\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_107", "timestamp": "2025-10-29T21:36:43.470981", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Antibiotic Associated Diarrhoea", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "In which infections is LIPosomal AMphotericin B used?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about LIPosomal AMphotericin B and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which LIPosomal AMphotericin B is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**LIPosomal AMphotericin B** is used in the treatment of:\n\n- Healthcare Associated Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_108", "timestamp": "2025-10-29T21:36:43.470984", "metadata": {"original_task_type": "drug_information", "drug": "LIPosomal AMphotericin B", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Aspergillus treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Aspergillus.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Aspergillus based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Aspergillus** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_109", "timestamp": "2025-10-29T21:36:43.470987", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Aspergillus", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "When should I prescribe Cloxacillin?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Cloxacillin and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Cloxacillin is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Cloxacillin** is used in the treatment of:\n\n- Diabetic foot infections (DFI)\n- Acute Osteomyelitis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_110", "timestamp": "2025-10-29T21:36:43.470990", "metadata": {"original_task_type": "drug_information", "drug": "Cloxacillin", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Antimicrobial Treatment Guidelines?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Antimicrobial Treatment Guidelines.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Antimicrobial Treatment Guidelines.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Antimicrobial Treatment Guidelines:\n\n**First-Line Treatment:**\n- MEROPENEM 1g (IV) for Not specified\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_111", "timestamp": "2025-10-29T21:36:43.470993", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Antimicrobial Treatment Guidelines", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Febrile neutropenia syndrome?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Febrile neutropenia syndrome.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Febrile neutropenia syndrome.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Febrile neutropenia syndrome:\n\n**First-Line Treatment:**\n- Piperacillin-tazobactam 4.5g (IV)\n- Cefoperazone-sulbactam 3g (IV)\n- Meropenem 1g (IV)\n\n**Alternative Options:**\n- Meropenem\n- Imipenem\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_112", "timestamp": "2025-10-29T21:36:43.470996", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Febrile neutropenia syndrome", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is Amoxicillin used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Amoxicillin and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Amoxicillin is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Amoxicillin** is used in the treatment of:\n\n- Community Acquired Pneumonia\n- Possible serious bacterial infection, PSBI (community acquired)\n- Neonatal Infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_113", "timestamp": "2025-10-29T21:36:43.471001", "metadata": {"original_task_type": "drug_information", "drug": "Amoxicillin", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Infections of Liver, Gall Bladder and Biliary tract?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Infections of Liver, Gall Bladder and Biliary tract.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Infections of Liver, Gall Bladder and Biliary tract.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Infections of Liver, Gall Bladder and Biliary tract:\n\n**First-Line Treatment:**\n- Metronidazole 750mg (IV or oral) for total 10 days\n- Ceftriaxone 2g (IV)\n- Metronidazole 750mg (q8h)\n\n**Alternative Options:**\n- Tinidazole\n- Piperacillin-tazobactam\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_114", "timestamp": "2025-10-29T21:36:43.471004", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Infections of Liver, Gall Bladder and Biliary tract", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Mucor treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Mucor.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Mucor based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Mucor** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_115", "timestamp": "2025-10-29T21:36:43.471007", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Mucor", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Streptobacillus moniliformis treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Streptobacillus moniliformis.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Streptobacillus moniliformis based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Streptobacillus moniliformis** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_116", "timestamp": "2025-10-29T21:36:43.471010", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Streptobacillus moniliformis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Streptococci treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Streptococci.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Streptococci based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Streptococci** is commonly associated with:\n\n- Acute Osteomyelitis\n\n**Effective antibiotics include:**\n- Cloxacillin\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_117", "timestamp": "2025-10-29T21:36:43.471013", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Streptococci", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about HSV treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for HSV.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against HSV based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**HSV** is commonly associated with:\n\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n- Conjunctivitis\n\n**Effective antibiotics include:**\n- TRIFLURIDINE\n- ACYCLOVIR\n- GENTAMICIN\n- FLUCONAZOLE\n- GANCICLOVIR\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_118", "timestamp": "2025-10-29T21:36:43.471016", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "HSV", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Bite wound infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Bite wound infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Bite wound infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Bite wound infections:\n\n**First-Line Treatment:**\n- Amoxicillin-clavulanic acid 625mg (PO) for 3 to 5 days\n- Piperacillin-tazobactam 4.5g (IV) for 5 to 7 days\n- Valacyclovir/Acyclovir for 7 days\n\n**Alternative Options:**\n- Cefuroxime\n- Doxycycline\n\n**Common Pathogens:** Staphylococcus aureus, Pasteurella multocida, Anaerobes\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_119", "timestamp": "2025-10-29T21:36:43.471020", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Bite wound infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Oropharyngeal Candidiasis", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Oropharyngeal Candidiasis.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Oropharyngeal Candidiasis\n\n**Definition:** Common local infection seen in infants, older adults who wear dentures, patients treated with antibiotics, chemotherapy or radiation therapy to the head and neck, and those with cellular immune deficiency like HIV.\n\n**First-Line Treatment (ICMR 2025):**\n- CLOTRIMAZOLE 10mg for 7 days\n- FLUCONAZOLE 200mg for 7-14 days\n- FLUCONAZOLE 100-150mg (3mg/kg for children) for 7-14 days\n\n**Special Populations:** Consider dose adjustments or alternative agents\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_120", "timestamp": "2025-10-29T21:36:43.471024", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Oropharyngeal Candidiasis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Entamoeba histolytica infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Entamoeba histolytica.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Entamoeba histolytica based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Entamoeba histolytica** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_121", "timestamp": "2025-10-29T21:36:43.471027", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Entamoeba histolytica", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Candida?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Candida.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Candida based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Candida** is commonly associated with:\n\n- Brain Abscess\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- FLUCONAZOLE\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_122", "timestamp": "2025-10-29T21:36:43.471030", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Candida", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Cytomegalovirus?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Cytomegalovirus.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Cytomegalovirus based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Cytomegalovirus** is commonly associated with:\n\n- Orbital Cellulitis and Retinitis\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- VANCOMYCIN\n- GANCICLOVIR\n- VALGANCICLOVIR\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_123", "timestamp": "2025-10-29T21:36:43.471034", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Cytomegalovirus", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Leptospira spp.?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Leptospira spp..", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Leptospira spp. based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Leptospira spp.** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_124", "timestamp": "2025-10-29T21:36:43.471037", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Leptospira spp.", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is ITRACONAZOLE used for?", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about ITRACONAZOLE and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which ITRACONAZOLE is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**ITRACONAZOLE** is used in the treatment of:\n\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n- Oropharyngeal Candidiasis\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_125", "timestamp": "2025-10-29T21:36:43.471040", "metadata": {"original_task_type": "drug_information", "drug": "ITRACONAZOLE", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Hemophilus influenzae treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Hemophilus influenzae.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Hemophilus influenzae based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Hemophilus influenzae** is commonly associated with:\n\n- Periocular infections (Eyelid infections, Orbital cellulitis)\n\n**Effective antibiotics include:**\n- AMOXICILLIN-CLAVULANATE\n- CEFTRIAXONE\n- AMOXICILLIN\n- CLINDAMYCIN\n- COTRIMOXAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_126", "timestamp": "2025-10-29T21:36:43.471043", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Hemophilus influenzae", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Aztreonam", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Aztreonam and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Aztreonam is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Aztreonam** is used in the treatment of:\n\n- CSF shunt infections\n- Febrile neutropenia syndrome\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_127", "timestamp": "2025-10-29T21:36:43.471046", "metadata": {"original_task_type": "drug_information", "drug": "Aztreonam", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "How do I treat Anaerobes infections?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Anaerobes.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Anaerobes based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Anaerobes** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_128", "timestamp": "2025-10-29T21:36:43.471049", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Anaerobes", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What are ESBL-producing bacteria?", "task_type": "education"}, "generator_reasoning_steps": ["Step 1: Concept Identification - Understanding the antimicrobial stewardship or resistance concept being queried.", "Step 2: Clinical Context - Relating the concept to real-world clinical practice and patient care.", "Step 3: Guideline Alignment - Connecting the concept to ICMR 2025 guidelines and recommendations.", "Step 4: Practical Implications - Explaining how this knowledge impacts antibiotic prescribing decisions.", "Step 5: Educational Response - Providing a clear, evidence-based explanation with practical examples."], "final_answer": "ESBL (Extended-Spectrum Beta-Lactamase) producing bacteria are organisms that produce enzymes capable of breaking down many common antibiotics, including:\n\n- Penicillins\n- Most cephalosporins\n- Aztreonam\n\n**Common ESBL producers:**\n- E. coli\n- Klebsiella species\n- Proteus mirabilis\n\n**Treatment options:**\n- Carbapenems (e.g., Meropenem, Imipenem)\n- Piperacillin-Tazobactam (for less severe infections)\n- Some fluoroquinolones (based on susceptibility)\n\nESBL infections require culture-guided therapy and strict infection control measures.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "EDUCATION_129", "timestamp": "2025-10-29T21:36:43.471052", "metadata": {"original_task_type": "education", "source": "AMR education"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Pasteurella multocida treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Pasteurella multocida.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Pasteurella multocida based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Pasteurella multocida** is commonly associated with:\n\n- Bite wound infections\n\n**Effective antibiotics include:**\n- Amoxicillin-clavulanic acid\n- Piperacillin-tazobactam\n- Valacyclovir/Acyclovir\n- Amoxicillin-Clavulanic acid\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_130", "timestamp": "2025-10-29T21:36:43.471057", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Pasteurella multocida", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Silver nitrate", "task_type": "drug_information"}, "generator_reasoning_steps": ["Step 1: Drug Identification - The query is about Silver nitrate and its clinical indications.", "Step 2: Guideline Search - Searching ICMR 2025 guidelines for syndromes where this drug is recommended.", "Step 3: Indication Analysis - Identifying all infections for which Silver nitrate is listed as first-line or alternative therapy.", "Step 4: Spectrum Assessment - Considering the drug's antimicrobial spectrum and its appropriateness for the listed indications.", "Step 5: Response Compilation - Listing all ICMR-approved indications with guideline references."], "final_answer": "**Silver nitrate** is used in the treatment of:\n\n- Burn wound infections\n\nThis antibiotic is recommended by ICMR 2025 guidelines for these infections.", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "DRUG_INFORMATION_131", "timestamp": "2025-10-29T21:36:43.471060", "metadata": {"original_task_type": "drug_information", "drug": "Silver nitrate", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about CMV treatment", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for CMV.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against CMV based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**CMV** is commonly associated with:\n\n- Gastro-intestinal (GI) Syndromes - Oesophagitis\n- Conjunctivitis\n\n**Effective antibiotics include:**\n- TRIFLURIDINE\n- ACYCLOVIR\n- GENTAMICIN\n- FLUCONAZOLE\n- GANCICLOVIR\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_132", "timestamp": "2025-10-29T21:36:43.471062", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "CMV", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Tell me about Botulism", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Botulism.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Botulism\n\n**Definition:** Botulism is a serious medical emergency that requires immediate treatment. Botulinum antitoxins to be administered as soon as possible, this can neutralize botulinum toxin and prevent further damage.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_133", "timestamp": "2025-10-29T21:36:43.471066", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Botulism", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Enteric fever?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Enteric fever.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Enteric fever.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Enteric fever:\n\n**First-Line Treatment:**\n- Azithromycin 20 mg /kg/day for 7 days\n- Cotrimoxazole 960 mg for 2 weeks\n- Ceftriaxone 2g (IV) for 10-14 days\n\n**Alternative Options:**\n- Cefixime\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_134", "timestamp": "2025-10-29T21:36:43.471070", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Enteric fever", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What should I know about Septic Abortion?", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Septic Abortion.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Septic Abortion\n\n**Definition:** Fever, Vaginal discharge, pelvic/abdominal pain, etc. Symptoms usually appear within 24 to 48 hours after an abortion.\n\n**First-Line Treatment (ICMR 2025):**\n- AMPICILLIN 2g for 7-10 days\n- GENTAMICIN 5 mg/kg for 7-10 days\n- METRONIDAZOLE 500 mg for 7-10 days\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_135", "timestamp": "2025-10-29T21:36:43.471074", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Septic Abortion", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Burn wound infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Burn wound infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Burn wound infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Burn wound infections:\n\n**First-Line Treatment:**\n- Silver sulfadiazine 1% (Topical)\n- Silver nitrate 0.5% (Topical)\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_136", "timestamp": "2025-10-29T21:36:43.471077", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Burn wound infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What is the first-line treatment for Septic Abortion?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Septic Abortion.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Septic Abortion.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Septic Abortion:\n\n**First-Line Treatment:**\n- AMPICILLIN 2g (IV) for 7-10 days\n- GENTAMICIN 5 mg/kg (IV) for 7-10 days\n- METRONIDAZOLE 500 mg (IV) for 7-10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_137", "timestamp": "2025-10-29T21:36:43.471081", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Septic Abortion", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics are recommended for Dental Infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Dental Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Dental Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Dental Infections:\n\n**First-Line Treatment:**\n- METRONIDAZOLE 400mg (PO) for 5 days\n- AMOXICILLIN 1g (PO) for Not specified\n- METRONIDAZOLE 400mg (PO) for Not specified\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_138", "timestamp": "2025-10-29T21:36:43.471085", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Dental Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Tertiary Peritonitis", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Tertiary Peritonitis.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Tertiary Peritonitis.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Tertiary Peritonitis:\n\n**First-Line Treatment:**\n- IMIPENEM-CILASTATIN 500 mg (IV) for 5-7 days\n- MEROPENEM 1g (IV) for 5-7 days\n\n**Alternative Options:**\n- POLYMYXIN B\n- COLISTIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_139", "timestamp": "2025-10-29T21:36:43.471088", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Tertiary Peritonitis", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What does ICMR recommend for treating Healthcare Associated Infections?", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Healthcare Associated Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Healthcare Associated Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Healthcare Associated Infections:\n\n**First-Line Treatment:**\n- MICAFUNGIN 100 mg (IV) for Not specified\n- ANIDULAFUNGIN 200 mg loading dose, then 100 mg daily (IV) for Not specified\n- CASPOFUNGIN 70 mg loading dose, then 50 mg daily (IV) for Not specified\n\n**Alternative Options:**\n- POLYMYXIN B\n- COLISTIN\n\n**Common Pathogens:** C. glabrata, C. auris, C. krusei\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_140", "timestamp": "2025-10-29T21:36:43.471092", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Healthcare Associated Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "List the first-line drugs for Urinary Tract Infections", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Urinary Tract Infections.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Urinary Tract Infections.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Urinary Tract Infections:\n\n**First-Line Treatment:**\n- NITROFURANTOIN 100 mg (PO) for 5 days\n- PIPERACILLIN-TAZOBACTAM 4.5g (IV) for 7-10 days\n\n**Alternative Options:**\n- COTRIMOXAZOLE\n- ERTAPENEM\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_141", "timestamp": "2025-10-29T21:36:43.471096", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Urinary Tract Infections", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Give me an overview of Acute Undifferentiated Febrile illness", "task_type": "syndrome_overview"}, "generator_reasoning_steps": ["Step 1: Syndrome Identification - Providing a comprehensive overview of Acute Undifferentiated Febrile illness.", "Step 2: Clinical Definition - Reviewing the ICMR definition and diagnostic criteria.", "Step 3: Pathogen Analysis - Identifying the most common causative organisms.", "Step 4: Treatment Protocol - Extracting first-line antimicrobial therapy recommendations.", "Step 5: Special Considerations - Noting any special population considerations or alternative regimens.", "Step 6: Summary Formulation - Presenting a complete clinical overview with guideline references."], "final_answer": "# Acute Undifferentiated Febrile illness\n\n**Definition:** Acute febrile syndrome presents with headache, chills, or muscle and joint pains and is usually viral and often resolves without treatment. Acute febrile syndrome can also be caused by bacterial, rickettsial or parasitic infections and non-infective conditions like autoimmune disorders.\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "SYNDROME_OVERVIEW_142", "timestamp": "2025-10-29T21:36:43.471099", "metadata": {"original_task_type": "syndrome_overview", "syndrome": "Acute Undifferentiated Febrile illness", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "What antibiotics work against Cryptococcus neoformans?", "task_type": "pathogen_treatment"}, "generator_reasoning_steps": ["Step 1: Pathogen Identification - The query concerns treatment options for Cryptococcus neoformans.", "Step 2: Syndrome Mapping - Identifying which clinical syndromes are commonly associated with this pathogen per ICMR guidelines.", "Step 3: Drug Selection - Finding antibiotics effective against Cryptococcus neoformans based on guideline recommendations.", "Step 4: Resistance Considerations - Noting any documented resistance patterns mentioned in the guidelines.", "Step 5: Treatment Summary - Compiling the effective antimicrobials with their indications."], "final_answer": "**Cryptococcus neoformans** is commonly associated with:\n\n- Brain Abscess\n\n**Effective antibiotics include:**\n- CEFTRIAXONE\n- CEFTAXIME\n- METRONIDAZOLE\n\n*Based on ICMR 2025 Guidelines*", "verifier_result": "Pass", "icmr_reference": "ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "PATHOGEN_TREATMENT_143", "timestamp": "2025-10-29T21:36:43.471102", "metadata": {"original_task_type": "pathogen_treatment", "pathogen": "Cryptococcus neoformans", "source": "ICMR 2025"}}
{"instruction": "Answer the following antimicrobial query according to ICMR 2025 Antimicrobial Treatment Guidelines.", "context": {"query": "Show me the treatment guidelines for Septic Abortion", "task_type": "guideline_lookup"}, "generator_reasoning_steps": ["Step 1: Query Analysis - The user is asking about treatment guidelines for Septic Abortion.", "Step 2: Guideline Reference - Consulting ICMR 2025 Antimicrobial Treatment Guidelines for evidence-based recommendations.", "Step 3: First-Line Therapy Identification - Identifying the recommended first-line antimicrobial agents for Septic Abortion.", "Step 4: Dosage and Route Verification - Extracting the correct dosages and routes of administration from the guidelines.", "Step 5: Alternative Options - Noting alternative therapeutic options when first-line agents are contraindicated.", "Step 6: Response Formulation - Providing a comprehensive answer with drug names, dosages, routes, and duration based on ICMR 2025 guidelines."], "final_answer": "According to ICMR 2025 Guidelines for Septic Abortion:\n\n**First-Line Treatment:**\n- AMPICILLIN 2g (IV) for 7-10 days\n- GENTAMICIN 5 mg/kg (IV) for 7-10 days\n- METRONIDAZOLE 500 mg (IV) for 7-10 days\n\n**Alternative Options:**\n- CLINDAMYCIN\n- GENTAMICIN\n\n\n*Reference: ICMR 2025 Guidelines, Page N/A*", "verifier_result": "Pass", "icmr_reference": "Page N/A, ICMR 2025 Guidelines", "confidence_score": 1.0, "validation_checks": [{"check": "Guideline Reference Check", "passed": true}, {"check": "Reasoning Completeness Check", "passed": true}], "case_id": "GUIDELINE_LOOKUP_144", "timestamp": "2025-10-29T21:36:43.471106", "metadata": {"original_task_type": "guideline_lookup", "syndrome": "Septic Abortion", "source": "ICMR 2025"}}
